Arch Biopartners Management

Management Kriterienprüfungen 3/4

Arch Biopartners' CEO ist Richard Muruve , ernannt in Aug 2009, hat eine Amtszeit von 14.83 Jahren. Die jährliche Gesamtvergütung beträgt CA$150.00K , bestehend aus 100% Gehalt und 0% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 15.22% der Aktien des Unternehmens, im Wert von $11.76M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 12.8 Jahre bzw. 14.1 Jahre.

Wichtige Informationen

Richard Muruve

Geschäftsführender

CA$150.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	100.0%
Amtszeit als Geschäftsführer	14.9yrs
Eigentum des Geschäftsführers	15.1%
Durchschnittliche Amtszeit des Managements	12.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	14.2yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Richard Muruve im Vergleich zu den Einnahmen von Arch Biopartners verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-CA$2m
Dec 31 2023	n/a	n/a	-CA$2m
Sep 30 2023	CA$150k	CA$150k	-CA$3m
Jun 30 2023	n/a	n/a	-CA$4m
Mar 31 2023	n/a	n/a	-CA$3m
Dec 31 2022	n/a	n/a	-CA$3m
Sep 30 2022	CA$113k	CA$113k	-CA$1m
Jun 30 2022	n/a	n/a	-CA$257k
Mar 31 2022	n/a	n/a	-CA$423k
Dec 31 2021	n/a	n/a	CA$308k
Sep 30 2021	CA$100k	CA$100k	-CA$1m
Jun 30 2021	n/a	n/a	-CA$3m
Mar 31 2021	n/a	n/a	-CA$7m
Dec 31 2020	n/a	n/a	-CA$6m
Sep 30 2020	CA$383k	CA$100k	-CA$5m
Jun 30 2020	n/a	n/a	-CA$4m
Mar 31 2020	n/a	n/a	-CA$2m
Dec 31 2019	n/a	n/a	-CA$2m
Sep 30 2019	CA$100k	CA$100k	-CA$2m
Jun 30 2019	n/a	n/a	-CA$2m
Mar 31 2019	n/a	n/a	-CA$3m
Dec 31 2018	n/a	n/a	-CA$3m
Sep 30 2018	CA$100k	CA$100k	-CA$3m
Jun 30 2018	n/a	n/a	-CA$3m
Mar 31 2018	n/a	n/a	-CA$2m
Dec 31 2017	n/a	n/a	-CA$2m
Sep 30 2017	CA$100k	CA$100k	-CA$2m

Vergütung im Vergleich zum Markt: RichardDie Gesamtvergütung ($USD109.35K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD673.68K).

Entschädigung vs. Einkommen: RichardDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Richard Muruve (53 yo)

14.9yrs

Amtszeit

CA$150,000

Vergütung

Mr. Richard Gabriel Muruve is a Co-Founder of Arch Biopartners Inc. and has been its Chief Executive Officer since August 2009 and President since May 12, 2010. Mr. Muruve served as Acting Chief Financial...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Richard Muruve	Co-Founder	14.9yrs	CA$150.00k	15.13% CA$ 11.8m
Daniel Muruve	Co-Founder	12.8yrs	CA$289.00k	3.19% CA$ 2.5m
Andrew Bishop	CFO & Director	no data	CA$289.00k	1.21% CA$ 943.8k
Justin MacDonald	Co-Founder & Principal Scientist	no data	keine Daten	keine Daten
Paul Beck	Co-Founder & Principal Scientist	no data	keine Daten	keine Daten
Aaron Benson	Director of Communications	less than a year	keine Daten	keine Daten

12.8yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: ACHF.FDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (12.8 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Richard Muruve	Co-Founder	18.9yrs	CA$150.00k	15.13% CA$ 11.8m
Daniel Muruve	Co-Founder	no data	CA$289.00k	3.19% CA$ 2.5m
Andrew Bishop	CFO & Director	14.3yrs	CA$289.00k	1.21% CA$ 943.8k
Claude Allary	Independent Director	10.3yrs	CA$289.00k	0.32% CA$ 250.5k
Richard Rossman	Independent Director	14.2yrs	keine Daten	3.33% CA$ 2.6m
Robert Hodges	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Hindrik Mulder	Member of Scientific Advisory Board	no data	keine Daten	keine Daten

14.2yrs

Durchschnittliche Betriebszugehörigkeit

63.5yo

Durchschnittliches Alter

Erfahrener Vorstand: ACHF.FDie Vorstandsmitglieder sind sehr erfahren ( 14.1 ).

Arch Biopartners Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023

Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate

Recent updates

Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Arch Biopartners Inc. Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023

Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

Arch Biopartners' Lead Drug Lsalt Peptide to Enter the Canadian Treatments for Covid-19 (Catco) Trial

Arch Biopartners Inc. Provides Update on Phase II Trial for LSALT Peptide

Arch Biopartners Inc. Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

Arch Biopartners Inc. Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

Arch Biopartners Inc. Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Arch Biopartners Inc. Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase Ii Trial for Lsalt Peptide

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients with Arch Biopartners Inc

Arch Biopartners Inc. announced that it has received CAD 0.645 million in funding

Arch Biopartners Inc. announced that it expects to receive CAD 0.645 million in funding

Arch Biopartners Inc, Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

Arch Biopartners Inc. Announces First Patient Dose in Phase II Trial to Treat Complications in COVID-19

Arch Biopartners Inc. Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter